Rick Popert MS FRCS (Urol) is a consultant urological surgeon at Guy’s and St Thomas’ NHS Foundation Trust. He has over 10 years experience as a Consultant, appointed in 1996, having completed his higher surgical training at Guy’s and urological research at King’s College Hospital. He qualified from St Bartholomew’s Hospital Medical College in 1985.
He has a specialist interest in prostate cancer surgery, dynamic prostate brachytherapy and laser prostatectomy as well as helping to provide a comprehensive general urological service to South East London.
Prostate Brachytherapy
(Dynamic Intra-Operative Day Case Procedure)
Mr Popert and Dr Beaney, a Consultant in Clinical Oncology, have the UK’s largest experience of single visit Dynamic Intra-Operative Prostate Brachytherapy, which they introduced to Guy’s & St Thomas’ following familiarisation visits to some of the largest brachytherapy centres in the USA and Europe. The Dynamic Brachytherapy Programme at Guy’s & St Thomas’ has been supported by the Guy’s & St Thomas’ Charity who donated nearly £ 1 Million to help establish the service in 2003.
Prostate Cancer Surgery
Mr Popert’s surgical expertise is in Open Radical Prostatectomy (Nerve Sparing and non-Nerve Sparing with wide excision for locally advanced disease) and he is helping to evaluate the place of Laparoscopic Robotic Assisted Radical Prostatectomy at Guy’s Hospital. He has undergone training in the procedure and visited specialist units in Detroit and the Cleveland Clinic in Ohio who use the DaVinci Robot routinely.
Laser Prostate Surgery
For benign prostatic disease, he has introduced the Holmium Laser Prostatectomy (HoLEP) service at Guy’s and has carried out over 180 enucleations with reduced bleeding and length of in patient stay compared with standard trans urethral prostatectomy (TURP). This procedure can be applied to any size of prostate (unlike vapourisation procedures), provides the most effective and long term relief of symptoms, confirmed in randomised clinical trials. It also has the advantage that tissue can be analysed to exclude prostate cancer.
« Back 
